HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Clinicians typically first turn to antiarrhythmic drugs, but switching up the order may be offer patients better outcomes.

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

CHICAGO, IL—Giving rivaroxaban (Xarelto; Bayer/Janssen) to adults under the age of 65, after an atrial fibrillation (AF) ...

The prevalence of obesity and overweight is extraordinarily high. Unsurprisingly, deaths related to obesity are on the rise, ...

In high- and standard-risk patients CAS and TCAR look good, but some worry about skill sets, learning curves, and ...

COVID-19 “magnified” preexisting disparities for rural patients as compared with their urban counterparts, one study author ...

Total and LDL cholesterol variability over time may be a biomarker for higher dementia risk and cognitive decline.

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

The latest data show healthy compensation levels and resilience, but the impact of ownership changes remains unclear.

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.